IMNR to halt Remune trial

Immune Response (IMNR) said it will not continue a Phase III study of Remune started by former partner Agouron Pharmaceuticals. Agouron, a subsidiary of Pfizer (PFE), terminated its development and marketing agreement in July for IMNR's Remune HIV-1 immunogen to treat HIV infection/AIDS (see BioCentury, July 9). IMNR said the decision to discontinue the trial was based on its calculation that the trial was unlikely to achieve its primary endpoint of showing that the addition of Remune to PFE's Viracept and Combivir from GlaxoSmithKline (GSK; LSE:GSK) delays time to virologic failure. ...